Floatz logo

TTI 101

Hepatocellular Cancer

Tvardi Therapeutics, IncorporatedSmall moleculePhase 1/2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

520 Active assets in the Hepatocellular Cancer cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

TTI 101 is also rated in:

idiopathic pulmonary fibrosisDormant
CCC
Indicative ·
54 / 100
View asset →
cancerDormant
CC
Indicative ·
42 / 100
View asset →
gastric adenocarcinomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →